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ABSTRACT 
 
A cell-free in vitro system to dissect the mechanism of the peroxisomal matrix protein 
import pathway is described. The system relies on a post-nuclear supernatant, as a source of 
peroxisomes and cytosolic components, which is generally fortified with specific 
recombinant proteins to increase yields. A typical in vitro assay comprises the following 
steps: 1) incubation of the post-nuclear supernatant with an in vitro synthesised 
35
S-labeled 
reporter protein; 2) treatment of the organelle suspension with a protease; and 3) SDS-
PAGE/autoradiography analysis. Both organelle-resident proteins and the corresponding 
shuttling receptors (PEX5L/S or PEX5L.PEX7) can be used as reporter proteins. Thus, 
different but complementary perspectives on the mechanism of this pathway can be 
obtained. The system recapitulates all the steps of the pathway, including 
monoubiquitination of PEX5L/S at the peroxisome membrane, and its ATP-dependent 
export back into the cytosol by PEX1/PEX6. An in vitro import(/export) experiment is 
completed in 24 hours. 
 
 
 
INTRODUCTION 
 
In their basic configuration, cell-free organelle-based in vitro protein import assays 
comprise three steps: 1) incubation of an organelle suspension with an in vitro synthesised 
35
S-labeled reporter protein harbouring a specific targeting sequence; 2) treatment of the 
organelle suspension with a vast amount of an aggressive protease to degrade the non-
imported reporter protein; and 3) analysis of organelle proteins by SDS-
PAGE/autoradiography. The experimental simplicity of these assays together with the fact 
that they employ a completely open experimental system (meaning that components can be 
added or removed in a expedite manner) are the reasons why they have been in use for so 
many decades now, yielding a wealth of information on how mitochondria, chloroplasts, 
endoplasmic reticulum and peroxisomes import their proteins 
1–4
.  
The application of this technique to the study of the peroxisomal matrix protein import 
machinery (PIM) has been particularly informative due to the variety of reporter proteins 
that can be used in these assays. Indeed, besides organelle-resident proteins containing a 
peroxisomal targeting signal (PTS) type 1 or a PTS type 2 (see Fig. 1a for details on these 
PTSs), also the corresponding shuttling receptors, PEX5L/S and the protein complex 
PEX5L.PEX7, can be used as reporter proteins (note that there are two main isoforms of 
PEX5, PEX5L and PEX5S; for simplicity we omit the L/S whenever a statement applies to 
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both; see also Fig. 1a). Thus, different but complementary perspectives on the PIM, each 
centered on a different component, can be obtained. 
Here we present a detailed protocol to perform these assays as well as several strategies to 
block the peroxisomal matrix protein import pathway at virtually any step. The protocol 
provided uses a post-nuclear supernatant (PNS) from mouse or rat liver as a source of 
peroxisomes and cytosolic components, but other sources (e.g., cultured cells) can also be 
used. Besides an in vitro synthesised 
35
S-labeled reporter protein, some common 
biochemical reagents and protein analysis equipment, only a few easy-to-obtain 
recombinant proteins are necessary to perform these assays. 
 
Development of the protocol 
 
Despite their simplicity and the large amounts of mechanistic data they can potentially 
generate, in vitro protein import systems were not very popular in the peroxisomal protein 
sorting field for many years. A major problem was the low import yields obtained with 
many of the reporter proteins tested in the early attempts 
5–9
. This, together with a lack of 
bona fide negative controls, made the interpretation of those experiments a difficult task. 
Two main reasons explain why peroxisomes yielded poor results when used in in vitro 
protein import assays with 
35
S-labeled matrix proteins as reporters. The first is related to the 
fact that the PIM is largely partitioned between the peroxisomal membrane and the cytosol. 
PIM components found mainly in the cytosol include the low abundance proteins PEX5 
and PEX7, as well as components of the ubiquitin cascade (see Fig. 1b and Ref.
10–12
). This, 
together with the fact that neither PEX5 nor PEX7 are present in the rabbit reticulocyte 
lysate (RRL) 
13,14
, the system generally used to synthesise 
35
S-labeled proteins, means that 
any attempt to use purified peroxisomes or even crude organelle fractions in in vitro import 
assays programmed with 
35
S-labeled peroxisomal matrix proteins was poised to produce 
poor results. 
The second reason stems from the fragility of peroxisomes and to the fact that the PTS1 
present in the vast majority of peroxisomal matrix proteins is not cleaved upon import 
15,16
. 
Thus, peroxisome suspensions (e.g., a PNS or a highly purified peroxisome fraction) are 
always contaminated with soluble PTS1-containing proteins that have leaked from the 
organelles during tissue homogenization, or simple manipulations such as organelle 
pelleting and resuspension procedures 
15,17
. This creates competition phenomena between 
the 
35
S-labeled reporter protein (be it a PTS1 protein or a PTS2 protein), and the 
endogenous PTS1 proteins at two crucial steps: 1) interaction with the endogenous 
shuttling receptor PEX5, and 2) interaction of the cargo protein-PEX5 complexes with the 
docking/translocation machinery (DTM) (see Fig. 1b). 
Almost paradoxically, the reasons behind the poor performance of peroxisomes in in vitro 
import assays containing 
35
S-labeled peroxisomal matrix proteins are also those behind the 
robustness and specificity of the PNS-based PEX5-centered in vitro assay, the first of the 
four in vitro systems here described to be developed 
18
. Indeed, the low abundance of 
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endogenous PEX5 in PNS as well as the presence of soluble import-competent PTS1 
proteins in these supernatants implies, on one hand, that the few nanograms of 
35
S-labeled 
PEX5 protein that are generally used in in vitro assays will not face much competition from 
the endogenous receptor and, on the other hand, that the 
35
S-labeled protein can interact 
with endogenous PTS1 proteins thus yielding the correct substrate for the DTM 
19
. Thus, a 
relatively large fraction of the 
35
S-labeled PEX5 added to these assays engages in protein 
transport to the peroxisome. This, together with the easily detectable biochemical 
alterations that PEX5 undergoes during its transient passage through the peroxisome (i.e., 
acquisition of a protease-protected status and monoubiquitination; 
20,21
) makes the PEX5-
centered in vitro assay one of the most useful and informative tools to study the PIM 
22–25
. 
In contrast to the PEX5-centered in vitro assay, which requires nothing else other than the 
components provided by a PNS and a few chemicals, all the other assays, namely the 
PEX7-, the PTS2-, and the PTS1-centered in vitro systems require some modifications to 
the basic protocol. We note that all these modifications are extremely simple but they do 
increase in a dramatic way the robustness, and thus the specificity, of these assays. 
The strategy to increase the import yields of PTS2 proteins from essentially 0 to 5-10% of 
the input reporter protein, consists in fortifying the PNS with a recombinant mutant PEX5L 
protein (e.g., C1PEX5L) which still harbours all the domains necessary to interact with 
the DTM and with the PEX7/PTS2 heterodimer but that is no longer competent in 
transporting PTS1 proteins to the organelle 
26
. In this way, the concentration of PEX5L 
species competent in the PTS2-mediated protein import pathway is increased (thus 
compensating the unavoidable dilution of the low abundance endogenous PEX5L protein in 
the assays) without raising also the concentration of protein complexes comprising PEX5 
and endogenous PTS1 proteins, which would compete with the PTS2 reporter protein at the 
DTM level. 
A similar fortification strategy is used in the PEX7-centered in vitro assays. Here, 
supplementation of the PNS with recombinant C1PEX5L already increases markedly the 
fraction of 
35
S-labeled PEX7 that targets the peroxisome, but even better results are 
obtained when both C1PEX5L and a recombinant PTS2 protein, the precursor of 
phytanoyl-CoA hydroxylase (prePHYH), are added to the PNS 
3
. It should also be noted 
that the C1PEX5L.PEX7.prePHYH trimeric complex is extremely stable (half-life of 3 
hours). Thus, for some specific purposes it may be advantageous to pre-assemble the 
trimeric complex in vitro before starting the import/export assay 
13
. 
Although endogenous PEX5 is surely a limiting factor also in the PTS1-centered in vitro 
assays, fortifying the PNS with recombinant PEX5 has either no effect or just increases the 
import yields by a 2-fold factor, depending on the reporter PTS1 protein. The presence of 
large amounts of endogenous soluble PTS1 proteins in PNS explains this phenomenon – as 
the concentration of PEX5 in the assay is increased so is the concentration of complexes 
comprising endogenous PTS1 proteins and PEX5, thus titrating the available DTMs. 
However, we have recently found that for some reporter PTS1 proteins this problem can be 
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circumvented. Indeed, pre-incubation of 
35
S-labeled 2,4-dienoyl-CoA reductase or sterol 
carrier protein x (SCPx) with a few nanograms of recombinant PEX5 before starting the 
import assay dramatically improves their in vitro import yields 
27
. In the case of SCPx this 
effect is particularly strong as import of this protein becomes almost completely dependent 
on the recombinant PEX5 with which it is pre-incubated. Although we are still lacking 
detailed data on the PEX5-SCPx interaction, this suggests that this protein complex is 
particularly stable, as is in fact supported by previous data on the interaction between the C-
terminal half of PEX5 and SCP2, a protein identical to the C-terminal fourth of SCPx 
28
. 
Thus, by starting the import assays with a pre-assembled PEX5-SCPx complex, 
competition between the 
35
S-labeled protein and endogenous PTS1 proteins for PEX5 
binding is avoided. Furthermore, because the amount of recombinant PEX5 used in the pre-
incubation step that is carried over to the in vitro import assay is small, the DTM titration 
problem referred to above is also avoided. 
 
Applications of the method 
 
The organelle-based in vitro assays described here reproduce all the steps of the 
peroxisomal matrix protein import pathway. These include: 1) transport of newly 
synthesised proteins into the peroxisome matrix 
13,14,26,27
, 2) monoubiquitination of PEX5 at 
the peroxisomal DTM 
21,29
, 3) extraction of monoubiquitinated PEX5 from the DTM into 
the cytosol by PEX1/PEX6 
17,22,25
, and 4) deubiquitination of PEX5 in the cytosol 
23,30,31
. 
Thus, within a single biological pathway, which can be fully recapitulated in vitro, several 
different subjects can be addressed, namely protein translocation across biological 
membranes, RING E3s and protein ubiquitination/deubiquitination, and mechanoenzymes 
of the AAA family. Given the increasing number of tools and strategies that can be used to 
block this pathway at virtually any step (see Table 1) it is clear that this experimental 
system will continue to provide valuable insights into the molecular mechanisms of all this 
machinery, similarly to what is true with all in vitro systems that have been used to study 
protein sorting to other organelles 
1,2,4
. 
The protocol presented here uses post-nuclear supernatants from rat/mouse liver as a source 
of peroxisomes and cytosolic components (see Box 1). There are two reasons behind this 
option: 1) peroxisomes are quite abundant in this organ 
32
, and 2) a PNS prepared from the 
liver of a single animal is sufficient to keep several researchers performing daily assays for 
several months. However, if necessary, PNS prepared from cultured cells can also be used, 
as described before for human skin fibroblasts from control individuals and Zellweger 
patients, CHO and HeLa cells 
22,33,34
. Thus, the protocol and experimental strategies 
presented here can potentially be applied to a variety of other cells (e.g., mouse embryonic 
fibroblasts) with minor or no adaptations. 
Finally, it may be important to note that although we find it particularly convenient to use 
35
S-labeled reporter proteins in these assays (authentic/untagged reporter proteins can be 
used; the results are obtained by a simple autoradiography which is semi-quantitative in 
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nature; and mammalian reporter proteins synthesised in a rabbit reticulocyte lysate tend to 
be fully soluble/active) a Western-blot/immunodetection procedure can also be employed to 
monitor these assays, as previously shown for endogenous rat liver PEX5 
17,18
 and, more 
recently, for a recombinant tagged version of Arabidopsis thaliana PEX5 
24
. The use of 
epitope-tagged reporter proteins in these assays is particularly promising because it may 
also facilitate future attempts to scale-up these assays for more quantitatively demanding 
purposes, such as structural studies of the DTM. 
 
Comparison with other methods 
 
Besides organelle-based in vitro assays, only one other type of in vitro assays is currently 
available to study the PIM. These are all cell-based assays which use semi-permeabilized 
cultured cells as a source of peroxisomes 
35–37
. In brief, cells are semi-permeabilized either 
mechanically or by treatment with substances that partially solubilize the plasma membrane 
(e.g., Streptolysin O), incubated with a reporter protein and analysed by 
(immuno)fluorescence microscopy. In one case, an ELISA-based detection method was 
coupled to the import assay to better assess the import efficiency of the reporter protein 
37
.  
There are advantages and disadvantages associated with those cell-based assays. The latter 
include the requirement of a continuous supply of live cells, and the need to use reporter 
proteins that have to be chemically different from any other protein already present in the 
semi-permeabilized cells; otherwise it will be difficult to distinguish a reporter protein from 
its endogenous pool. A major advantage of those assays resides in the fact that the methods 
used to prepare semi-permeabilized cells are very gentle and comprise a washing step of the 
cells just before the import assays. Thus, there are no soluble endogenous PTS1 proteins 
competing with PTS1 or PTS2 reporter proteins in those assays. This is probably the reason 
why cell-based in vitro import assays, in contrast to the organelle-based assays described 
here, can be used to study the import pathway of proteins harboring a weak PTS1 (e.g., 
catalase 
36
). 
 
Experimental design 
 
Organelle-based in vitro assays are very simple to perform and very fast. Preparation of 
some reagents can consume a few days but since all these can be stored frozen for many 
months (e.g., the PNS; recombinant proteins) or even years (e.g., plasmids encoding the 
reporter proteins for in vitro transcription/translation), this part of the work is seldom 
performed. With the exception of the reduced glutathione and N-ethylmaleimide (NEM) 
solutions, which are prepared freshly, all reagents are kept at 4 ºC or stored in small 
aliquots at either -20 ºC or -70 ºC and thawed just before starting the in vitro assay. 
When performing this type of assays, it is important to know that when a protein, whatever 
it is, is incubated with an organelle suspension, a fraction of it will always be recovered 
together with the organelles upon centrifugation (e.g., see Ref. 
38
). The fraction of that 
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protein that sediments with the organelles may simply reflect the amount of supernatant 
that is always entrapped in the organelle pellet, or may in fact be larger if the protein has 
some tendency to aggregate or to interact non-specifically with organelle membranes. If, in 
addition to this phenomenon, one also considers that some proteins may be intrinsically 
protease-resistant, then it is easy to understand why improperly controlled experiments can 
provide deceiving conclusions. 
The protocol presented here provides a number of independent strategies that efficiently 
block protein import/export into/from peroxisomes (i.e., negative controls) and thus any 
unspecific phenomena, as the ones described above, will be easily identified. For instance, 
addition of recombinant NDPEX14 (see Table 1) to an import assay completely blocks the 
PEX5-, PEX7-, PTS1-, and PTS2-centered in vitro assays, whereas addition of a vast 
excess of recombinant prePHYH to an in vitro assay programmed with a 
35
S-labeled PTS2 
protein will block (compete with) import of the reporter protein without blocking insertion 
of PEX7 into the peroxisomal DTM. Likewise, addition of a recombinant protein 
comprising the PTS1-binding domain of PEX5 (referred to as TPRs; see Table 1) to a 
PEX5-centered in vitro assay, or its presence in the pre-incubation mixture containing 
35
S-
labeled SCPx and recombinant PEX5, will block the PTS1-dependent insertion of 
35
S-
labeled PEX5 into the DTM and peroxisomal import of 
35
S-labeled SCPx, respectively.  
Another frequently used strategy to ensure that an in vitro assay is working properly 
consists in assessing the amounts of reporter protein that acquire an organelle-associated, 
protease-protected status in a time- and temperature-dependent manner. Naturally, after 
protease treatment no reporter protein should be detected in organelles in the 0-min time 
point and the same result should be obtained when the in vitro assay is performed at 0-4 ºC, 
because insertion of receptor-cargo protein complexes into the DTM does not occur at this 
temperature 
26,27
. Although these experiments should not be taken as true negative controls 
(artifacts may also be time- and/or temperature-dependent), an unexpected result (e.g., 
“import” in a 0-4 ºC sample) indicates the existence of problems with either the reporter 
protein or the proteolysis conditions. 
The experimental conditions used here in the protease-treatment step are rather harsh: 500-
600 µg of total PNS protein containing 1-2 µL of a rabbit reticulocyte lysate in a 100 µL 
volume are treated with 40 µg of an aggressive protease (e.g., proteinase K or pronase) for 
30-45 min on ice. For the reporter proteins used here, these conditions are far in excess of 
those required to completely degrade the soluble 
35
S-labeled proteins under identical 
conditions. However, this is not necessarily true for other proteins, many of which are 
actually peroxisomal matrix proteins. Thus, when using a reporter protein for the first time 
its intrinsic susceptibility to aggressive proteases has to be determined. This is easily 
performed by incubating 0.5-1 µL aliquots of the RRL containing the 
35
S-labeled protein 
with different concentrations of a protease (e.g., proteinase K, pronase or trypsin) in 100 µL 
of import buffer, and following steps 6-B-ii, 6-A-iv and 7-11 of the main protocol. Samples 
are then analysed by SDS-PAGE/Western-blot/autoradiography, as described (see also Box 
2). 
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Once the robustness and specificity of the in vitro assays is established, many different 
tools/strategies can be used to block the PIM at different steps. Some of these are as simple 
as decreasing the temperature of the assays, or adding non-hydrolysable ATP analogs, 
whereas others require mutant versions of the recombinant or 
35
S-labeled proteins 
mentioned here. A summary of all the tools/strategies currently used is presented in Table 
1. 
 
Limitations 
 
The PEX5-, PEX7-, and PTS2-centered in vitro assays are all very robust. However, the 
PTS1-centered in vitro system still presents some limitations. Indeed, not all PTS1-
containing cargo proteins can be used in these assays. For instance, proteins such as 
catalase, alanine glyoxylate aminotransferase and glutathione S-transferase κ 1 show no, or 
almost no, import when used in these assays. A possible reason for this may be the weak 
PTS1 they harbour 
39
, which probably translates into short half-lives of their complexes 
with PEX5. Thus, a pre-incubation step with recombinant PEX5 before in vitro import, the 
strategy used here for SCPx, does not really improve their import yields because the 
complexes probably dissociate in a few seconds after starting the import assay. 
The in vitro system described here can be used in biochemical complementation assays to 
identify and/or characterize components of the peroxisomal protein import machinery other 
than just PEX5 and PEX7 (e.g., the ubiquitin conjugation enzymes E2D1/2/3 
33
, the 
deubiquitinase USP9X 
30
, and the adaptor protein AWP1 
40
). However, due to the fact that 
organelles from wild type rat/mouse are used in this protocol, only soluble components can 
be studied in this manner because only these can be removed from or added to the organelle 
suspension. Clearly, for the membrane-embedded components of the peroxisomal protein 
import machinery other approaches will have to be used. 
 
MATERIALS 
 
REAGENTS 
 
 Male rat or mouse with 6-10 weeks of age fasted overnight (e.g., specific pathogen free 
Wistar Han rat (strain code: 273) or C57BL/6 mouse (strain code: 027) from Charles 
River). The animals used here were handled in accordance with the protocols approved 
by the IBMC Animal Ethics Committee (CEA – Comissão de Ética Animal). 
Experimental protocols were approved by the Portuguese General Veterinarian Board 
(DGAV – Direcção Geral de Alimentação e Veterinária). ! CAUTION Experiments 
using rodents must conform to national and institutional regulations. 
 Plasmids encoding PEX5L (pGEM4-PEX5 18), PEX7 (pGEM4-PEX7 3), SCPx 
(pGEM4-SCPx 
27
) and pre-thiolase (pGEM4-pre-thiolase 
26
) for in vitro 
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transcription/translation (all available on request). Plasmid DNA is prepared using a 
standard miniprep kit (e.g., Qiagen, cat. no. 27104).  
 Plasmids encoding the following N-terminally histidine-tagged proteins for expression 
in Escherichia coli: PEX5L, C1PEX5L, NDPEX14 (all available on request), and 
prePHYH 
41
 (see Box 3). 
 3-(N-Morpholino)propanesulfonic acid (MOPS) (Sigma-Aldrich, cat. no. M1254) 
 Adenosine 5′-(β,γ-imido)triphosphate lithium salt hydrate (AMP-PNP) (Sigma-Aldrich, 
cat. no. A2647) 
 Acetone (Merck, cat. no. 100014) 
 ATP disodium salt hydrate (Sigma-Aldrich, cat. no. A2383) 
 Bromophenol blue (Sigma-Aldrich, cat. no. B5525) 
 Di-sodium hydrogen phosphate (Na2HPO4) (Merck, cat. no. 106586) 
 Dithiothreitol (DTT) (Calbiochem®, cat. no. 233155) 
 EasyTag L-[35S]-Methionine, 1 mCi (37MBq), Stabilized Aqueous Solution (Perkin 
Elmer, cat. no. NEG709A001MC) (
35
S-Met) ! CAUTION Radioactive compound. 
Safety precautions are required. Check that your institution holds the appropriate 
license for radioisotope usage. 
 Ethanol (PanReac AppliChem, cat. no. 121086) ! CAUTION Highly flammable. 
 Ethylenedinitrilotetraacetic acid disodium salt dihydrate (EDTA) (Merck, cat. 
no.108421) ! CAUTION Toxic, avoid inhalation. 
 HCl (Merck, cat. no. 100317) ! CAUTION Very corrosive. Avoid exposure. 
 HIS-Select® Nickel Affinity Gel (Sigma-Aldrich, cat. no. P6611) 
 Imidazole (Sigma-Aldrich, cat. no. I0125) 
 Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Calbiochem®, cat. no. 420322) 
 KCl (Merck, cat. no. 104936) 
 KOH (Merck, cat. no.105033) ! CAUTION Corrosive and toxic, avoid contact and 
spillage. 
 L-Glutathione reduced (GSH) (Sigma-Aldrich, cat. no. G4251)  
 Liquid nitrogen ! CAUTION Extremely cold. Handle with care. 
 L-Methionine (Met) (Sigma-Aldrich, cat. no. M9625) 
 Luria Broth (LB) and LB agar plates with the appropriate antibiotics (see Box 3) 
 MgCl2 (Merck, cat. no. 105833) 
 N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide (E-64) (Sigma-Aldrich, cat. 
no. E3132) 
 NaCl (Merck, cat. no. 106404) 
 NaOH (Merck, cat. no. 106498) ! CAUTION Very corrosive. Avoid exposure. 
 N-ethylmaleimide (NEM) (Sigma-Aldrich, cat. no. E3876) ! CAUTION Very toxic. 
Avoid exposure.  
 Nitrocellulose membrane 0.45 µm (e.g., Amersham, cat. no. 10600002) 
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 Phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich, cat. no. P7626) ! CAUTION 
Corrosive and toxic. Avoid exposure. 
 Ponceau S (Sigma-Aldrich, cat. no. P3504) ! CAUTION Toxic. Avoid exposure. 
 Protease from Streptomyces griseus type XIV (Pronase) (Sigma-Aldrich, cat. no. 
P5147) ! CAUTION Toxic. Avoid exposure. 
 Protease inhibitor cocktail (Sigma-Aldrich, cat. no. P8340) 
 Proteinase K from Tritirachium album (PK) (Sigma-Aldrich, cat. no. P2308) ! 
CAUTION Toxic. Avoid exposure. 
 Sodium dihydrogen phosphate monohydrate (NaH2PO4*H2O) (Merck, cat. no. 106346) 
 Sucrose (Sigma-Aldrich, cat. no. S0389) 
 TNT® T7 Quick Coupled Transcription/Translation System (Promega, cat. no. L1170) 
 Trichloroacetic acid (TCA) (PanReac AppliChem, cat. no. 131067) ! CAUTION Very 
corrosive. Avoid exposure. 
 Tris(hydroxymethyl)aminomethane (Tris) (Merck, cat. no. 108382) 
 TritonTM X-100 (TX-100) (Sigma-Aldrich, cat. no. T9284)  
 Ubiquitin aldehyde (Ubal) (e.g., Enzolifesciences, cat. no. BML-UW8450-0050) 
 Ubiquitin from bovine erythrocytes (Ub) (Sigma-Aldrich, cat. no. U6253) 
 Vivaspin® 2 Sample Concentrators (GE Healthcare Life Sciences, cat. no. 28932247) 
 X-ray film (e.g., Kodak BioMax® MR, VWR, cat. no. 730-3241) 
 
EQUIPMENT 
 
 Hair dryer 
 Heating plate (e.g., VMS-A, VWR, cat. no. 442-0185) 
 High-speed centrifuge (e.g., Sorvall RC5B Plus with SS-34 and GS3 rotors and the 
corresponding tubes) 
 Low-speed microcentrifuge (e.g., VWR MiniStar silverline, cat. no. 521-2844) 
 Medium-speed centrifuge with adaptors for 15 mL falcon tubes (e.g., Hettich Universal 
320R, Sigma-Aldrich, cat. no. Z722871) 
 Orbital shaker incubator or shaking water bath for liquid bacterial cultures 
 Overhead stirrer (e.g., Sigma-Aldrich, cat. no. Z336645) equipped with a Potter-
Elvehjem Teflon pestle and glass tube (tight fitting) (Sigma-Aldrich, cat. no. P7984) 
 Petri dish 
 pH meter (e.g., WTW Inolab pH 720, GeminiBV, cat. no. 3321 HWK) 
 Refrigerated microcentrifuge (e.g., Eppendorf ® 5418R, cat. no. 5401000013) 
 Scissors 
 Sonopuls HD 2200 Sonicator (Bandelin electronic, cat. no. HD2200) equipped with a 
MS 73 tip (Bandelin electronic, cat. no. 492) 
 Spectrophotometer (e.g., Thermo Scientific Genesys 10S, cat. no. 840-208100) 
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 Standard equipment and solutions required to perform SDS-PAGE/Western-
blot/autoradiography 
 Thermomixer (e.g., Eppendorf® Comfort, Sigma-Aldrich, cat. no. T3317) 
 
REAGENT SETUP 
 
▲CRITICAL STEP Doubly distilled and deionized water (ddH2O) should be used to 
prepare all aqueous solutions. 
 
0.1 M ATP pH 7.0 Dissolve 275.57 mg of ATP disodium salt in 4 mL of water and add 
100 μL of 1 M MOPS-KOH pH 7.2. After adjusting pH to ~7.0 with 5 M NaOH, make up 
to 5 mL with water. Store 500-µL aliquots at -70 °C. Stable for at least one year.  
 
1 M DTT Dissolve 1.5 g of DTT in 10 mL (final volume) of water. Store 500-µL aliquots 
at -20 °C. Stable for several months. 
 
0.4 mg/mL E-64 Dissolve 4 mg of E-64 in 9.9 mL of water and add 100 μL of 1 M MOPS-
KOH pH 7.2. Store 500-μL aliquots at -20 °C. Stable for several months. 
 
0.5 M EDTA-NaOH pH 8.0  Add 18.6 g of EDTA to 70 mL of water. Adjust pH to 8.0 
with 5 M NaOH and make up to 100 mL with water. Store at room temperature (~ 23 ºC). 
Stable for several months. 
 
20% (v/v) Ethanol Dilute 20 mL of ethanol in 100 mL (final volume) of water. Store at 
room temperature. Stable for years. 
 
0.1 M GSH Dissolve 30.73 mg of GSH in 500 μL of water. Add 20 μL of 1 M MOPS-
KOH pH 7.2 and adjust pH to ~7.0 with 5 M NaOH. Make up to 1 mL with water. 
▲CRITICAL STEP This solution should be prepared freshly and kept on ice. 
 
1 M Imidazole Dissolve 6.8 g of imidazole in 100 mL (final volume) of water. Store at 4 
ºC in the dark. Stable for at least two years. 
 
1 M IPTG Dissolve 477 mg of IPTG in 2 mL (final volume) of water. Store 500-μL 
aliquots at -20 °C. Stable for at least one year. 
 
3 M KCl Dissolve 11.2 g of KCl in 50 mL (final volume) of water. Store at room 
temperature. Stable for years.  
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5 M KOH Dissolve 28.1 g of KOH in 100 mL (final volume) of water. Store at room 
temperature. Stable for at least one year. ! CAUTION Corrosive and toxic, avoid contact 
and spillage. 
 
3 g/L L-Methionine Dissolve 30 mg of methionine in 10 mL (final volume) of water. Store 
500-μL aliquots at -20 °C. Stable for years. 
 
2 M MgCl2 Dissolve 20.3 g of MgCl2 in 50 mL (final volume) of water. Store at room 
temperature. Stable for at least one year.  
 
1 M MOPS-KOH pH 7.2 Dissolve 20.9 g of MOPS in 60 mL of water, adjust pH to 7.2 
(20 °C) using a 5 M KOH solution and make up to 100 mL with water. Store at 4 °C. Stable 
for at least six months.  
 
5 M NaCl Dissolve 29.2 g of NaCl in 100 mL (final volume) of water. Store at room 
temperature. Stable for years. 
 
5 M NaOH Dissolve 20 g of NaOH in 100 mL (final volume) of water. Store at room 
temperature. Stable for at least one year. ! CAUTION Very corrosive. Avoid exposure.  
 
0.1 M NEM Dissolve 6.25 mg of NEM in 500 μL of water. ▲CRITICAL STEP Prepare 
fresh and keep on ice. ! CAUTION Extremely hazardous! Handle with care. 
 
50 mg/mL PMSF Dissolve 50 mg of PMSF in 1 mL (final volume) of ethanol. Store at -20 
°C. Stable for at least one year. ! CAUTION Corrosive and toxic. Avoid exposure. 
 
Ponceau S solution Dissolve 0.2 g of Ponceau S and 3 g of TCA in 100 mL (final volume) 
of water. Store at room temperature. ! CAUTION This solution contains TCA. Handle 
with care. Stable for at least one year. 
 
20 mg/mL Protease (PK or pronase) Dissolve 10 mg of the protease in 490 μL of water 
plus 10 μL of 1 M MOPS-KOH pH 7.2. Centrifuge solution at 11,300g for 15 min at 4 °C 
and store single use 25-μL aliquots of the supernatant at -70 °C. Stable for at least one year.  
 
Radioactive ink Dilute 2 L of 35S-Met in 1 mL of 20% (v/v) ethanol. Spike with some 
grains of bromophenol blue. Store at room temperature. Stable for several months. ! 
CAUTION Radioactive compound. Safety precautions are required.  
 
0.5 M Sodium phosphate buffer pH 8.0 Prepare 50 mL of 0.5 M Na2HPO4 by dissolving 
3.5 g in 50 mL (final volume) of water. Prepare 50 mL of 0.5 M NaH2HPO4 by dissolving 
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3.4 g in 50 mL (final volume) of water. Adjust the pH of the 0.5 M Na2HPO4 solution to 
pH 8.0 with 0.5 M NaH2PO4. Store at 4 ºC. Stable for at least one year. 
 
100% (w/v) TCA Dissolve 100 g of TCA in 100 mL (final volume) of water. Store at room 
temperature. ! CAUTION Very corrosive. Avoid exposure. Stable for at least one year. 
 
1 M Tris pH 8.0 Dissolve 12.1 g in 70 mL of water. Adjust pH to 8.0 with concentrated 
HCl and make up to 100 mL. Store at 4 ºC. Stable for at least one year. 
 
20% (w/v) TX-100 Dilute 20 g of TX-100 in 100 mL (final volume) of water. Store at 4 
ºC. Stable for at least one year. 
 
1.25 mM Ub Dissolve 5.35 mg of bovine ubiquitin in 500 μL of water. Store 100-μL 
aliquots at -70 °C. Stable for at least one year. 
 
Import buffer 6x Import buffer 6x is 1.5 M sucrose, 300 mM KCl, 120 mM MOPS pH 
7.2, 18 μg/mL methionine and 18 mM MgCl2. Dissolve 5.1 g of sucrose in 1.2 mL of 1 M 
MOPS-KOH pH 7.2, 1 mL of 3 M KCl, 90 μL of 2 M MgCl2, and water to 10 mL (final 
volume). Store 250-µL aliquots at -20 °C. Stable for at least one year. Before using, 
supplement the 250-µL aliquot with 1.5 μL of 3 g/L methionine. 
 
SEM buffer SEM buffer is 0.25 M sucrose, 20 mM MOPS-KOH pH 7.2 and 1 mM 
EDTA-NaOH pH 8.0. Dissolve 21.4 g of sucrose in 100 mL of water. Add 5 mL of 1 M 
MOPS-KOH pH 7.2, 0.5 mL of 0.5 M EDTA-NaOH pH 8.0, and make up to 250 mL with 
water. Store at 4 ºC, stable for several weeks. 
 
SEMK buffer SEMK buffer is SEM buffer supplemented with 80 mM KCl. Dissolve 21.4 
g of sucrose in 100 mL of water. Add 5 mL of 1 M MOPS-KOH pH 7.2, 6.67 mL of 3 M 
KCl, 0.5 mL of 0.5 M EDTA-NaOH pH 8.0, and make up to 250 mL with water. Store at 4 
ºC, stable for several weeks. 
 
Bacteria lysis buffer A Lysis buffer A is 50 mM Tris pH 8.0, 150 mM NaCl, 1 mM DTT, 
0.1% (w/v) TX-100, 50 µg/mL PMSF and 1:1000 (v/v) of protease inhibitor cocktail. Mix 5 
mL of 1 M Tris pH 8.0, 3 mL of 5 M NaCl and 500 μL of 20% (w/v) TX-100. Make up to 
100 mL with water and store at 4 ºC. Stable for several months. Before using, supplement 
30 mL with 30 μL of 1 M DTT, 30 μL of 50 mg/mL PMSF and 30 μL of protease inhibitor 
cocktail. 
 
Bacteria lysis buffer B Lysis buffer B is 20 mM sodium phosphate buffer pH 8.0, 500 mM 
NaCl, 0.1% (w/v) TX-100, 10 mM imidazole, 50 µg/mL PMSF and 1:1000 (v/v) of 
protease inhibitor cocktail. Mix 4 mL of 0.5 M sodium phosphate buffer pH 8.0, 10 mL of 
14 
5 M NaCl, 1 mL of 1 M imidazole and 500 μL of 20% (w/v) TX-100. Make up to 100 mL 
with water and store at 4 ºC. Stable for several months. Before using, supplement 30 mL 
with 30 μL of 50 mg/mL PMSF and 30 μL of protease inhibitor cocktail. 
 
Washing buffer A Washing buffer A is 50 mM sodium phosphate buffer pH 8.0, 150 mM 
NaCl. Mix 10 mL of 0.5 M sodium phosphate buffer pH 8.0 with 3 mL of 5 M NaCl and 
make up to 100 mL with water. Store at 4 ºC. Stable for several months. 
 
Washing buffer B Washing buffer B is 50 mM sodium phosphate buffer pH 8.0, 500 mM 
NaCl. Mix 10 mL of 0.5 M sodium phosphate buffer pH 8.0 with 10 mL of 5 M NaCl and 
make up to 100 mL with water. Store at 4 ºC. Stable for several months. 
 
Elution buffer Elution buffer is 50 mM sodium phosphate buffer pH 8.0, 150 mM NaCl, 
250 mM imidazole, 1 mM DTT. Mix 1.5 mL of 0.5 M sodium phosphate buffer pH 8.0, 
450 μL of 5 M NaCl, 3.75 mL of 1 M imidazole and 15 μL of 1 M DTT, and make up to 15 
mL with water. Prepare fresh and keep on ice. 
 
Protein storage buffer Storage buffer is 50 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA-
NaOH pH 8.0, 1 mM DTT. Mix 5 mL of 1 M Tris pH 8.0, 3 mL of 5 M NaCl, 200 μL of 
0.5 M EDTA-NaOH pH 8.0, and make up to 100 mL with water. Store at 4 ºC. Stable for 
several months. Before using, supplement 20 mL with 20 μL of DTT 1 M and keep on ice. 
 
Rat/mouse liver post-nuclear supernatant in SEM (see Box 1). 
 
35
S-labeled reporter protein (e.g., PEX5L, PEX7, pre-thiolase, or SCPx) Synthesize using 
the TNT
®
 T7 Quick Coupled Transcription/Translation System as per manufacturer 
instructions (see Box 2). Aliquots can be stored at -70 ºC for a few months. 
 
Histidine-tagged recombinant proteins: PEX5L, C1PEX5L, NDPEX14, and prePHYH 
(see Box 3). 
 
PROCEDURE 
 
In vitro import(/export) protocol ● TIMING 3-5 hours 
 
1. Rapidly thaw, while gently mixing, an aliquot of the rabbit reticulocyte lysate 
containing the relevant 
35
S-labeled reporter protein. Immediately put it on ice and 
dilute it according to Table 2. The volumes provided are for two import(/export) 
reactions. Scale-up volumes as needed for a different number of reactions. Also, 
increase all volumes by 10% because they are not additive. 
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▲CRITICAL STEP The amount of 35S-lysate may be decreased or increased 
depending on the specific activity of the radiolabeled protein. Pre-dilution of the lysate 
in import buffer decreases pipetting errors in subsequent steps. 
2. Prepare the PNS mix according to Table 3. 
▲CRITICAL STEP PNS should be quickly thawed in your hands, gently tapping the 
tube several times. Once thawed, place it on ice and use immediately. Any thawed PNS 
that is not used is discarded. 
3. (Optional) Prime the PNS for import by incubating it 5 min at 37 ºC. 
▲CRITICAL STEP This is a mandatory step only when using experimental 
conditions that block export of PEX5 from the DTM (e.g., assays containing AMP-
PNP, GST-Ub, or apyrase; see Table 1). If the PNS is not primed for import, 
endogenous PEX5 at the peroxisomal DTM will not be extracted by the ATP-
dependent export machinery and therefore the number of available DTMs will be 
small. Whenever this is not the case, skip this step. 
4. Assemble the final reactions according to Table 4.  
5. Gently flick the tube to mix the components, spin down for 1 sec in a low-speed 
microcentrifuge to collect all the content at the bottom of the tube and incubate for 30 
min at 37 ºC. 
6. In vitro import(/export) assays generally include a protease treatment step to degrade 
reporter proteins that did not enter peroxisomes. However, this also destroys the 
soluble pools of shuttling receptors that travelled through the DTM during step 5. 
Thus, two options are provided here, one in which the protease treatment step is 
skipped (option A) and the other which includes it (option B). Option A is particularly 
informative in the PEX5-centered assay due to the fact that PEX5 is monoubiquitinated 
during its passage through the DTM. It can also be applied to PEX7, but in this case a 
two-step import/export strategy would have to be followed (see Ref. 
3
) because PEX7 
is not covalently modified at the DTM. 
A) Analysis of organelle and cytosolic proteins (no protease treatment): 
i) Place the tubes on ice, add 25 L of 0.1 M NEM (20 mM final concentration) 
to each sample and incubate for 5 min. 
▲CRITICAL STEP NEM is a powerful alkylating agent that is commonly 
used to stop ubiquitination/deubiquitination reactions. It also neutralizes other 
thiol groups that might disrupt the ubiquitin-PEX5 thioester bond during 
sample processing/analysis.  
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ii) Dilute the reactions gently to 1 mL with ice-cold SEMK. Centrifuge at 11,300g 
for 15 min at 4 °C. 
iii) Transfer 500 μL of the supernatants (equivalent to 250 g of PNS) to a new 
microtube. Discard the remaining supernatant. 
▲CRITICAL STEP Avoid cross-contamination between pellet and 
supernatant. If necessary, after removing most of the supernatant, briefly spin 
down the tube and remove any traces of supernatant using a 100 L pipette. 
iv) Precipitate the pellets and the supernatants with 10% (w/v) TCA (final 
concentration): add 55 μL of 100% (w/v) TCA to the supernatants, and 550 μL 
of 10% (w/v) TCA to the organelle pellets. Proceed to step 7. 
! CAUTION TCA is very corrosive. Handle with care. 
B) Analysis of organelle-associated protease-protected proteins (protease treatment): 
i) Place the tubes on ice, add 2 L of the selected protease at 20 mg/mL (400 
g/mL final concentration), mix gently, spin down for 1 sec in a low-speed 
microcentrifuge and incubate for 40 min on ice. 
▲CRITICAL STEP The protease solution should be quickly thawed in hands, 
put on ice, and promptly used. 
▲CRITICAL STEP A brief spin down is critical to ensure that the entire 
sample gets in contact with the protease. 
ii) Add 1 L of PMSF 50 mg/mL, mix gently, spin down 1 sec in a low-speed 
microcentrifuge and incubate for 2 min on ice to inactivate the protease. 
▲CRITICAL STEP PMSF in the stock solution precipitates on ice. Before 
use, keep it at room temperature (~ 23 °C) and, if necessary, vortex to ensure all 
PMSF is in solution. 
▲CRITICAL STEP A brief spin down is critical to ensure that all protease 
gets in contact with PMSF. 
iii) Dilute the reactions gently to 1 mL with ice-cold SEMK. Centrifuge at 11,300g 
for 15 min at 4 °C to isolate the organelles. 
iv) Discard the supernatant. 
▲CRITICAL STEP The supernatant should be thoroughly removed. If 
necessary, after removing most of it, briefly spin down the tube and remove all 
traces using a 100 L pipette. 
v) Add 1 mL of 10% (w/v) TCA to the organelle pellets. 
! CAUTION TCA is very corrosive. Handle with care. 
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▲CRITICAL STEP The TCA precipitation minimizes protease reactivation. 
7. Vortex and incubate on ice for 30 minutes. 
8. Centrifuge at 11,300g for 15 min at 4 °C. Discard the supernatant. 
9. Wash the protein pellets with 1 mL of acetone. Vortex thoroughly and centrifuge at 
11,300g for 15 min at 4 °C. 
■ PAUSE POINT While in acetone, samples can be stored at -20 ºC for some days. 
10. Discard the supernatant. Spin down for 1-2 sec and remove the remaining acetone. 
11. Dry protein pellets at 37 ºC (2-5 min). 
▲CRITICAL STEP Acetone interferes with protein solubilization in Laemmli 
sample buffer; ensure it has evaporated completely. 
SDS-PAGE/Western-blot/Autoradiography ● TIMING 3-4 hours for SDS-PAGE/ 
Western-blot plus 12-16 hours for autoradiography 
12. Prepare samples for SDS-PAGE analysis. Note that two different SDS-containing 
sample buffers are used here. Whenever the aim of the experiment is to detect 
monoubiquitinated PEX5 use the modified non-reducing Laemmli sample buffer 
described in Option A. For all other situations use the classical reducing Laemmli 
sample buffer and the procedure described in Option B. 
A) Protein solubilization with modified Laemmli sample buffer (non-reducing): 
i) Resuspend protein pellets (from organelle and soluble fractions) in Laemmli 
sample buffer 1x lacking reducing agents and containing instead 10 mM NEM. 
▲CRITICAL STEP To detect monoubiquitinated PEX5, thiol-based reducing 
agents (such as DTT or β-mercaptoethanol) cannot be added to the loading 
sample buffer, otherwise the thioester bond that links ubiquitin to cysteine 11 of 
PEX5 will be disrupted. 
ii) Incubate samples for 30 min at 45 ºC with shaking. 
iii) Spin down for 30 sec at 11,300g to collect samples at the bottom of the tube. 
B) Protein solubilization with Laemmli sample buffer (reducing): 
vi) Resuspend protein pellets in Laemmli sample buffer 1x containing 100 mM 
DTT. 
vii) Incubate samples for 10 min at 65 ºC and then 5 min at 90 ºC with shaking. 
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viii) Spin down for 30 sec at 11,300g to collect samples at the bottom of the tube. 
13. Load protein samples onto an SDS-gel. For experiments containing only organelle 
pellets load the equivalent to 500 g of PNS protein per lane. When analyzing 
equivalent amounts of both cytosolic supernatants and organelle pellets load the 
material obtained from 80-125 g of PNS protein per lane, to avoid gel overloading 
problems. Also, load one lane with molecular-weight standards and another with the 
original 
35
S-labeled protein prepared in either classical or modified Laemmli sample 
buffer, as appropriate (e.g., 5-10% of the amount used in each assay). SDS-gels can be 
run under standard conditions but, when the aim is to detect the labile 
monoubiquitinated PEX5 species, better results are obtained when gels are run in a 
cold room (4 ºC). 
14. Transfer the proteins from the gel onto a nitrocellulose membrane (Western-blot) using 
a standard semi-dry apparatus. 
15. Stain the membrane with the Ponceau S solution for 1 min. Destain with a large 
volume of water for a few seconds until the membrane (but not the protein bands) is 
almost white. 
! CAUTION Contains TCA. Very corrosive. Handle with care.  
▲CRITICAL STEP Check that protein loadings were as planned and that samples 
were not degraded during processing/analysis. 
? TROUBLESHOOTING  
16. Place the Ponceau S-stained membrane in a completely transparent plastic cover (e.g., 
a transparent sheet protector) and make a digital record of it using a standard computer 
scanner or any other high-resolution device. 
 
17. Mark the membrane with small radioactive ink dots alongside the molecular-weight 
markers. Dry the membrane using a hair dryer. 
▲CRITICAL STEP The radioactive dye will help aligning the film with the Ponceau 
S-stained membrane. Dry slowly, keeping the hair dryer 10-20 cm away from the 
nitrocellulose membrane. Nitrocellulose is an explosive and it will burn completely if 
heated too much! On the other hand, note that if the membrane is not completely dried 
it will stick to the x-ray film. 
18. Expose the membrane to an x-ray film overnight in an exposure cassette. 
19. On the next day, develop the film. 
? TROUBLESHOOTING  
20. Analyze results. 
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? TROUBLESHOOTING  
 
● TIMING 
STEP 1-11, in vitro import(/export) protocol: 3-5 hours. 
STEP 12-20, SDS-PAGE/Western-blot/Autoradiography: 3-4 hours for SDS-PAGE/ 
Western-blot plus 12-16 hours for autoradiography. 
Box 1, preparation of rat/mouse liver post-nuclear supernatant (PNS): ~1 hour. 
Box 2, synthesis of radiolabeled proteins: ~2 hours for in vitro synthesis plus 3-6 hours for 
SDS-PAGE/Western-blot/autoradiography analysis. 
Box 3, expression and purification of recombinant proteins: 4-5 days. 
 
TROUBLESHOOTING 
 
Step Problem Possible reason Possible solution 
15 Disappearance of high 
molecular weight protein 
bands in one or several lanes 
in the Ponceau S-stained 
membrane. 
Protease was not properly 
inactivated or became active 
during sample processing/SDS-
PAGE analysis. 
Make sure the protease in the stock solution 
is completely solubilized. 
Use a fresh stock of PMSF. 
Be sure to remove as much supernatant as 
possible after step 6-B-iv. 
If the reporter protein is highly susceptible 
to protease treatment, the protease 
concentration in step 6-B-i may be 
decreased, or a less aggressive protease may 
be used. For instance, reactivation of 
trypsin is very rare whereas proteinase K 
reactivates with some frequency.  
19 The membrane is glued to the 
x-ray film. 
The membrane was not properly 
dried. 
Do not attempt to detach the membrane 
from the film. Just immerse the film and 
membrane in a tray with water and shake 
gently until the two separate. Stain, dry, and 
expose the membrane to a new x-ray film.  
20 Low import yields of the 
PTS1 reporter protein. 
Not enough recombinant PEX5 
was added during the pre-
incubation step or to the import 
reaction. 
Titrate the amount of recombinant PEX5 
needed for optimum import yields. 
Different cargoes have different 
requirements. 
The reporter protein has a weak 
PTS1. 
Proteins harbouring a weak PTS1 are not 
imported in this in vitro system. Use other 
systems (e.g., see Ref. 
35–37
). Alternatively, 
mutating the PTS1 into a stronger version 
might increase its in vitro import yield. 
20 A radioactive band migrating 
a few kDa above 
35
S-labeled 
PEX5 is observed in the input 
This band probably represents a 
DTT-sensitive oxidative adduct 
between radiolabeled PEX5 and 
Pre-incubate the rabbit reticulocyte lysate 
containing radiolabeled PEX5 with 0.5 mM 
DTT for 5 min on ice before the dilution 
20 
sample upon SDS-PAGE 
under non-reducing 
conditions. 
the abundant hemoglobin protein 
from the lysate. 
step (step 1). 
20 NDPEX14 did not inhibit 
import of the reporter PTS1 
protein. 
The PTS1 protein oligomerized 
during synthesis and is 
intrinsically protease-resistant. A 
fraction of the reporter protein is 
thus recovered in the protease-
treated organelle pellets.   
Synthesise a new batch of reporter protein 
in the presence of recombinant PEX5. 
Alternatively, decrease the incubation time 
of the protein synthesis step to 30-60 min. 
See Box 2. 
 
 
ANTICIPATED RESULTS 
 
The protocol detailed above describes the basic configuration of organelle-based in vitro 
import assays using as reporter proteins either radiolabeled peroxisomal matrix proteins 
(containing a PTS1 or PTS2) or the corresponding shuttling receptors (PEX5 and 
PEX5L.PEX7). All assays include a suitable negative control sample to attest for the 
specificity of the experiments. 
Fig. 2a shows a PEX5-centered in vitro import assay performed in presence ubiquitin 
aldehyde (Ubal; see Table 1) and either ATP or the non-hydrolysable analogue AMP-PNP. 
The experiment clearly shows that in the presence of AMP-PNP only organelle-associated 
PEX5 is monoubiquitinated. Substituting ATP for AMP-PNP leads to the appearance of 
monoubiquitinated PEX5 in the cytosolic fraction of the assays, reflecting export of DTM-
embedded Ub-PEX5 into the cytosol, a process catalysed by the ATP-dependent 
mechanoenzymes PEX1/PEX6. The relationship between organelle-associated Ub-PEX5 
and soluble Ub-PEX5 could be easily confirmed by performing a two-step import/export 
assay, in which organelles from an AMP-PNP-containing assay are isolated by 
centrifugation, resuspended in import buffer, and incubated in the presence of ATP 
30
. Fig 
2b shows that PEX5 is indeed covalently modified by an ubiquitin molecule – addition of 
the ubiquitin analog GST-Ub to the assay increases the molecular mass of the modified 
PEX5 species by ca. 30 kDa, the molecular mass of GST. Finally, the fact that 
monoubiquitinated PEX5 is no longer detected when samples are treated with thiol-
containing reagents before SDS-PAGE analysis indicates that the ubiquitin is linked to 
PEX5 through a thioester bond. Identical in vitro assays performed with 
35
S-labeled 
PEX5(C11K) and PEX5(C11A) would show that cysteine 11 of PEX5 is the ubiquitinated 
residue 
23
. 
Fig. 2c shows the typical results of the PTS1-centered in vitro assay using 
35
S-labeled SCPx 
as the reporter protein. Note how import of SCPx is almost completely dependent on the 
pre-incubation step with recombinant PEX5 – a chemically identical assay, but in which the 
pre-incubation step was omitted, shows essentially no protease-protected SCPx (compare 
lanes 2 and 3). To demonstrate that the protease-resistant radiolabeled SCPx reflects 
authentic peroxisomal import, one control reaction was performed in the presence of 
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NDPEX14. This recombinant protein binds to PEX5 and inhibits the PEX5-mediated 
import of SCPx (compare lane 4 with lane 5). The complete protease-treated import 
reaction (i.e., the organelle suspension obtained after step 6-B-ii of the protocol) can also be 
subjected to nycodenz gradient centrifugation to demonstrate that the reporter protein co-
sediments with pure peroxisomes 
26,27
. 
Fig. 2d shows the result of an in vitro import assay where both 
35
S-pre-thiolase, a PTS2 
protein, and 
35
S-PEX7 were used as reporter proteins. Note the marked increase in yields 
when recombinant C1PEX5L is added to the assays (compare lanes 1 and 3). Note also 
that a fraction of protease-protected 
35
S-labeled pre-thiolase was converted into a faster 
migrating species (lanes 3 and 5). This reflects processing of the precursor protein into its 
mature form, a relatively fast event in vivo and in vitro 
26,42
. Some PTS1 proteins (e.g., 
acyl-CoA oxidase 1 and SCPx) also undergo processing at the peroxisome matrix. 
However, these events are much slower, requiring many hours to be detected in vivo 
42–44
. 
Thus, they are barely detected in in vitro assays. 
The amount of organelle-associated protease-resistant 
35
S-labeled PEX7 in these assays can 
be further increased by supplementing the import reaction with a recombinant PTS2 
protein, in casu prePHYH (Fig 2d, compare lanes 3 and 4). As expected, in the presence of 
recombinant prePHYH, but not mature PHYH (matPHYH) lacking the PTS2, protease-
resistant 
35
S-pre-thiolase is no longer detected (Fig. 2d, compare lanes 4 and 5), reflecting 
competition with the more abundant recombinant PTS2 protein. Again, NDPEX14 
completely blocks entry of 
35
S-PEX7 into the organelle (compare lane 6 with lane 4). In the 
assay shown in lane 2, recombinant C1PEX5S was used instead of C1PEX5L. These 
two recombinant proteins are almost identical, except for the fact that C1PEX5S lacks an 
internal 37 amino acid domain present in C1PEX5L, which contains the PEX7-bindind 
domain. As expected, neither reporter protein acquired a protease-protected status under 
these conditions, in agreement with the fact that only the large isoform of PEX5 is 
competent in the PTS2-mediated protein import pathway 
45
. 
 
FIGURE LEGENDS 
 
Figure 1. The PEX5-mediated protein import pathway. 
a) Peroxisomal matrix proteins possess within their polypeptide chain one of two 
peroxisomal targeting signals: a PTS1 or a PTS2. The PTS1 is a small C-terminal peptide, 
usually ending in S-K-L 
16
. The PTS2 is a degenerated nonapeptide present at the N-termini 
of a few peroxisomal proteins, which contrary to the PTS1 is cleaved upon import 
46,47
. The 
PEX5 transcript undergoes alternative splicing yielding a small and a large isoform, PEX5S 
and PEX5L, respectively 
45
. The first does not interact with PEX7/PTS2 and thus only 
participates in the PTS1-mediated protein import pathway; the second transports both types 
of cargo proteins to the peroxisome 
45,48
. b) The mechanism of the PIM. Cytosolic PEX5 
(Stage 0 PEX5) forms a complex with newly synthesised matrix proteins (CP; Stage 1a). 
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The receptor-cargo complex then docks at the peroxisomal membrane 
docking/translocation machinery (DTM; Stage 1b) where it becomes inserted (Stage 2) 
resulting in the release of the cargo protein into the organelle matrix. PEX5 is then 
monoubiquitinated at cysteine 11 (Stage 3a), recognized by the receptor export module 
(REM; Stage 3b) and extracted in an ATP-dependent step yielding cytosolic 
monoubiquitinated PEX5 (Stage 4). Finally, the ubiquitin moiety is removed probably by a 
combination of enzymatic (USP9X) and non-enzymatic events (e.g., by nucleophiles such 
as glutathione; GSH) yielding free PEX5 (Stage 0). PEX7, the co-receptor for PTS2-
proteins, remains bound to PEX5 during most of the steps of the PTS2-mediated protein 
import pathway. For simplicity, PEX7 is not shown in the figure. Several strategies/tools to 
block this pathway at different steps (shown in red; ) are also indicated. Abbreviations 
used: C11S/A, PEX5 protein mutated version with the conserved cysteine 11 replaced by a 
serine or an alanine residue; CP, cargo protein; cyt, cytosol; DTM, docking/translocation 
module; E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; GSH, 
glutathione; GST-Ub, glutathione S-transferase ubiquitin fusion protein; IAA, 
iodoacetamide; NDPEX14, recombinant protein comprising the soluble N-terminal domain 
of PEX14; REM, receptor export module; mat, peroxisomal matrix; TPRs, recombinant 
protein comprising only the PEX5 tetratricopeptide repeats domain; Ub, ubiquitin; Ubal, 
ubiquitin aldehyde. 
 
Figure 2. Receptor- and cargo-centered in vitro import assays: 
a) PEX5-centered in vitro import assay: export of monoubiquitinated PEX5 is an ATP-
dependent step. Radiolabeled PEX5L was subjected to in vitro import reactions in the 
presence of Ubal and either ATP or AMP-PNP. After incubation, NEM-treated reactions 
were centrifuged to separate organelles (P) from supernatants (S). Samples (derived from 
100 µg of PNS protein) were then subjected to SDS-PAGE under nonreducing conditions. 
The membrane was probed with anti-PEX14 (a peroxisomal membrane protein) and anti-α-
Tubulin (a cytosolic protein). Lane I, 10% of the radiolabeled protein used in the total 
reactions. The Ponceau S-stained membrane is also shown. b) PEX5 is monoubiquitinated 
at a cysteine residue. Radiolabeled PEX5L was incubated with a PNS in import buffer 
supplemented with AMP-PNP and either ubiquitin (Ub) or GST-ubiquitin (GST-Ub). 
NEM-treated organelles were then isolated and analysed under nonreducing (-DTT) and 
reducing conditions (+DTT) by SDS-PAGE/Western-blot/autoradiography. Lane I, 25% of 
the radiolabeled protein used in each assay. The Ponceau S-stained membrane is shown. c) 
In vitro import of radiolabeled SCPx. Radiolabeled SCPx was subjected to in vitro import 
reactions in the presence of ATP and in the absence (lane 1) or presence of recombinant 
PEX5L (lanes 2-5). PEX5L was either added after the final reaction is assembled (lane 2) 
or pre-incubated with radiolabeled SCPx included in the lysate mix (lanes 3-5). Where 
indicated, NDPEX14 or PEX19 (a protein involved in a different aspect of peroxisome 
biogenesis 
49
) were included in the reactions (lanes 4 and 5, respectively). PK-treated 
organelles were subjected to SDS-PAGE/Western-blot/autoradiography. Lanes I1 and I2, 
23 
10% of the radiolabeled protein used in the assays shown in lanes 1 and 2, and lanes 3-5, 
respectively. To assess protein loadings, the membrane was probed with anti-Catalase (a 
peroxisomal matrix protein). The Ponceau S-stained membrane is also shown. d) In vitro 
import of radiolabeled PEX7 and pre-thiolase. Radiolabeled PEX7 and pre-thiolase 
(preThiol) were subjected to in vitro import reactions in the absence (-) or presence (+) of 
the indicated recombinant proteins. Pronase-treated organelles were then analysed by SDS-
PAGE/Western-blot/autoradiography. MatThiol, mature form of thiolase. Lane I, 5% of the 
radiolabeled proteins used in the assays. To assess protein loadings, the membrane was 
probed with anti-Catalase. The Ponceau S-stained membrane is also shown. 
 
TABLES 
 
Table 1. Tools/strategies to stimulate or block the peroxisomal protein import pathway. 
 
PEX5L Recombinant full length PEX5L. Generally used to stimulate import of PTS1-
containing cargo proteins 
14,27
. Concentration in the assay should be titrated for 
each PTS1 reporter cargo protein. Pre-incubation of recombinant PEX5 with 
some PTS1 proteins dramatically increases their import yields. 
ΔC1PEX5L A protein comprising the first 324 amino acid residues of PEX5L. It contains 
all the domains necessary to interact with PEX7/PTS2 and the DTM, but it does 
not interact efficiently with PTS1 proteins 
19,50
. Supplementing import reactions 
with recombinant ΔC1PEX5L boosts the PTS2-mediated import pathway. It 
bypasses competition with endogenous PTS1-containing proteins 
3,26
. 
PEX5L(N526K) Full length PEX5L containing the mutation N526K. This protein cannot bind 
PTS1 proteins efficiently, but like ΔC1PEX5L, is competent in the PTS2-
mediated protein import pathway 
51,52
. Supplementing import reactions with 
recombinant PEX5L(N526K) boosts the PTS2-mediated import 
3,26
. 
TPRs C-terminal half of PEX5 (amino acids 315-639 of PEX5L) comprising its 
tetratricopeptide repeats domain which is necessary for efficient PTS1 cargo 
binding 
52
. It is import incompetent because it lacks the N-terminal domains 
required for interaction with the DTM 
53
. The recombinant protein is used to 
sequester both 
35
S-labeled and endogenous PTS1-containing proteins. Thus, it 
blocks both import of PTS1 reporter proteins and the PTS1-mediated insertion 
of 
35
S-labeled PEX5 into the DTM 
19,27,54
. 
PEX5L(C11S)/ 
PEX5L(C11A) 
Full length PEX5L in which cysteine 11 was replaced by a serine or an alanine, 
respectively. These mutant PEX5L species can promote one cycle of protein 
transport to the peroxisome matrix. However, they are export-incompetent 
because they cannot be monoubiquitinated efficiently. Thus, they accumulate at 
24 
the DTM 
21,23
.  
PEX5L(C11K) Full length PEX5L in which cysteine 11 was replaced by lysine. This protein is 
functional in both the import and export steps. Monoubiquitination at the lysine 
residue yields an isopeptide bond which is much more stable than the thioester 
bond linking ubiquitin to the cysteine residue in wildtype PEX5L. Thus, SDS-
PAGE can be performed under reducing conditions 
23
. 
PEX5L-EGFP Full length PEX5L with a C-terminal EGFP tag. This bulky PEX5 fusion 
protein becomes inserted into the DTM and is monoubiquitinated. However, 
although monoubiquitinated PEX5L-EGFP is recognized by the REM, it is not 
efficiently released into the cytosol. A partially dislocated species accumulates 
in in vitro assays 
55
. 
NDPEX14 Recombinant protein comprising the first 80 amino acid residues of human 
PEX14, a component of the DTM 
56
. This domain binds with high affinity the 
diaromatic motifs present in the N-terminal half of PEX5, which are essential 
for PEX5 function 
57,58
. Used to inhibit import of all cargoes and insertion of 
the corresponding receptors into the DTM 
3,27
. 
PrePHYH Recombinant precursor of phytanoyl-CoA hydroxylase, a PTS2 protein used to 
stimulate targeting of PEX7 to the peroxisome 
3,13
. 
Import at  
<16 ºC 
PEX5-cargo protein complexes dock at the DTM but insertion of PEX5 into the 
DTM and cargo translocation are inhibited 
27
. 
Import at 
16<T<26 ºC 
Insertion of PEX5 into the DTM and cargo-translocation occur at these 
temperatures, but the ubiquitin conjugating cascade is compromised. Thus, 
PEX5 export is greatly diminished and thus more PEX5 is detected at the DTM 
27,59
.  
Apyrase Apyrase is an ATP-diphosphatase that hydrolyses ATP and other NTPs 
60
, 
effectively blocking PEX5 monoubiquitination and export 
26
. PEX5 will 
accumulate at the DTM. Pre-treat both the lysate and the ATP-primed PNS mix 
with 5-20 U/mL for 2 min at 37 ºC. 
Iodoacetamide  Iodoacetamide is an alkylating agent that modifies cysteine 11 of PEX5 
54
. 
Alkylated PEX5 cannot be monoubiquitinated and, consequently, the receptor 
accumulates at the DTM. 
ATPγS/ 
AMP-PNP 
Non-hydrolysable ATP analogues such as ATPγS or AMP-PNP are excellent 
substrates for the ubiquitin activating enzyme 
61
. Thus, PEX5 
monoubiquitination occurs normally in the presence of these nucleotides. 
However, they inhibit the AAA ATPases that comprise the REM and thus Ub-
PEX5 becomes trapped at the DTM 
21,30
. 
25 
GST-Ub GST-Ub is a recombinant fusion protein comprising glutathione S-transferase 
and ubiquitin. This molecule is efficiently used by the ubiquitin-conjugating 
cascade and can be coupled to cysteine 11 of PEX5. However, it acts as a 
dominant-negative analogue of ubiquitin, completely blocking export of 
monoubiquitinated PEX5 from the DTM 
21
. 
Ubal Ubiquitin aldehyde is an ubiquitin in which the C-terminal glycine carboxyl 
group was synthetically modified to an aldehyde 
62
. It is a potent and highly 
specific inhibitor of most deubiquitinases including USP9X, the enzyme that 
acts on cytosolic Ub-PEX5 (note that DTM-embedded Ub-PEX5 is not a 
substrate for deubiquitinases) 
30
. Use at 1-2 M. 
 
Table 2. PEX5, PEX7, PTS2, or PTS1 lysate mix for 2 reactions (Rx). 
 
  Reporter Protein 
   PEX5, PEX7, pre-thiolase SCPx* 
Components 
Amount/ 
concentration 
V (µL) V (µL) 
Import buffer 6x 1x 3.3 3.3 
ddH2O to 20 µL 14.7 13.7 
After mixing these components, add: 
PEX5L 20 ng/µL 20 ng - 1 
35S-Lysate 2 µL 2 2 
Final Volume   20 20 
* For SCPx, incubate the lysate mix for 15 min at 37 ºC. 
 
Table 3. PNS mix for 2 reactions (Rx). 
 
Components 
Amount/ 
concentration 
V (µL) 
Import buffer 6x 1x 16.7 
ddH2O to 100 µL 81.9 - x 
ATP 0.1 M 0.4 mM 0.4 
E-64 0.4 mg/mL 4 µg/mL 1 
After mixing these components, add: 
PNS (40-90 µg/µL) 1 mg x 
Final Volume 
 
100 
 
Table 4. Receptor- and cargo protein-centered in vitro reaction assembly. 
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  Reporter Protein 
  
PEX5 PEX7 SCPx pre-thiolase 
 
  ATP AMP-PNP  - +NDP14*  - +NDP14*  - +NDP14* 
Components 
Amount/ 
concentration 
V (µL) V (µL) V (µL) V (µL) V (µL) V (µL) V (µL) V (µL) 
Import buffer 6x 1x 6.7 6.7 6.7 6.7 6.7 6.7 6.7 6.7 
ddH2O 
 
29.3 29.3 25.9 25.9 27.5 27.5 26.1 26.1 
ATP 0.1 M   3 mM 3 -  3 3 3 3 3 3 
AMP-PNP 0.1 M  3 mM - 3 - - - - - - 
GSH 0.1 M  2 mM - - 2 2 2 2 2 2 
After mixing these components, add: 
C1PEX5L 0.2 µg/µL 100 ng/Rx - - 0.5 0.5 - - 0.5 0.5 
prePHYH 2 µg/µL 0.5 µg/Rx - - 0.25 0.25 - - - - 
NDPEX14 10 µg/µL 9 µg/Rx - - - 0.9 - - - 0.9 
Protein Storage Buffer   - - 0.9 - - - 0.9 - 
Ubal 0.5 mM  1 µM 0.2 0.2 - - - - - - 
Ub 1.25 mM  10 M 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 
After mixing these components, add:             
PNS mix  
 
50 50 50 50 50 50 50 50 
Incubate for 1 min at 37 ºC and then add:             
Lysate mix 
 
10 10 10 10 10 10 10 10 
 
  Final Volume of each reaction (Rx) = 100 µL 
* NDP14 – recombinant NDPEX14 
 
Box 1 
Preparation of rat/mouse liver post-nuclear supernatant (PNS) ● TIMING ~1 hour 
 
▲CRITICAL STEP Ensure that all materials and solutions are ice-cold. 
 
1. Euthanize one rat/mouse and immediately open the abdominal cavity using scissors. 
! CAUTION Experiments using rodents must conform to national and institutional 
regulations.  
 
2. Collect the liver and wash it with ice-cold SEM buffer. Blot it briefly onto paper 
towels, and weight it. 
 
3. Put the liver in a petri dish standing on ice and cut it into small pieces using scissors.  
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4. Transfer the liver pieces to the ice-cold Potter-Elvehjem glass tube and add a total of 4 
mL of ice-cold SEM buffer supplemented with 1:200 (v/v) of E-64 stock solution per 
gram of liver. 
 
5. Homogenize the liver with 1-2 strokes of the Teflon pestle working at 600 rpm. 
▲CRITICAL STEP Only 1-2 strokes are used to minimize organelle disruption. 
 
6. Transfer the total homogenate to a centrifuge tube (e.g., for rotor SS-34) and centrifuge 
at 600g for 10 min at 4 °C. Transfer the supernatant to a clean centrifuge tube pre-
cooled on ice and repeat the centrifugation step. The supernatant of this last 
centrifugation is the PNS. 
 
7. Snap freeze single-use aliquots (e.g., 100-200 µL in microtubes) in liquid N2 and store 
at -70 °C.  
! CAUTION When handling liquid nitrogen, always use personal protective 
equipment including insulated leather gloves and eye and face protection.  
■ PAUSE POINT When stored at -70 ºC, the PNS remains active for many months. 
 
8. Determine protein concentration of the PNS (e.g., using the Bradford method). It 
should be around 40-90 µg/µL. 
 
Box 2 
Synthesis of radiolabeled proteins ● TIMING ~ 2 hours for in vitro synthesis plus 3-6 
hours for SDS-PAGE/Western-blot/autoradiography analysis 
 
! CAUTION Wear gloves and follow appropriate laboratory procedures to handle 
radioactive material.  
▲CRITICAL STEP To avoid RNase contamination, microtubes and pipette tips should 
be RNase-free. Reserve a new box/package of these materials for this purpose and always 
handle them wearing clean gloves. 
1. Assemble a 50 L TNT® T7 Quick Coupled Transcription/Translation reaction 
according to the manufacturer instructions and synthesise the 
35
S-labeled reporter 
protein. 
▲CRITICAL STEP Some PTS1 proteins (e.g., catalase, acyl-CoA oxidase 1, and 
urate oxidase) have been shown to homo-oligomerize during in vitro synthesis yielding 
protease-resistant species. Addition of recombinant PEX5L (0.1-1 µM) at the 
beginning of the synthesis reaction prevents this, and yields soluble, protease-sensitive 
monomeric species, which, in at least two cases, are much better import substrates than 
the corresponding oligomeric forms (
14,50
). Alternatively, decrease the suggested time 
28 
of protein synthesis from 90 min to 30-60 min (homo-oligomerization is concentration- 
and time-dependent). 
2. Aliquot the rabbit reticulocyte lysate containing 35S-labeled reporter protein (e.g., 5-L 
aliquots) and store at -70 ºC. Keep a 0.5 L aliquot to check for correct protein 
synthesis. 
■ PAUSE POINT Aliquots can be stored at -70 ºC for a few months (take into 
consideration the half-life of 
35
S – 87 days). 
3. Add 20 L of Laemmli sample buffer 1x containing 100 mM DTT to the 0.5 L 
aliquot saved above, incubate for 5 min at 90 ºC with shaking and subject to SDS-
PAGE.  Load one lane of the gel with molecular-weight markers. 
4. Subject the gel to Western-blot/autoradiography, as described in steps 14-17. Expose 
the membrane to an x-ray film for 1-2 h, and develop the film. A strong signal 
corresponding to the 
35
S-labeled protein should be visible on the autoradiograph. 
 
Box 3 
Expression and purification of recombinant proteins ● TIMING 4-5 days 
Several recombinant proteins are required to perform the basic experiments described in the 
“PROCEDURE” section. These are: 
 PEX5L, the large isoform of human PEX5 (histidine-tagged protein; expression 
plasmid/E. coli strain: pQE30-PEX5/M15 
63
); 
 C1PEX5L, a protein comprising the first 324 residues of PEX5L (histidine-tagged 
protein; expression plasmid/E. coli strain: pET28a-C1PEX5L/BL21(DE3) 33); 
 NDPEX14, the N-terminal domain of PEX14, a small recombinant protein 
comprising the first 80 residues of human PEX14 (histidine-tagged protein; 
expression plasmid/E. coli strain: pQE30-NDPEX14/XL1
56
); and 
 prePHYH, the precursor of human phytanoyl-CoA hydroxylase, a PTS2-containing 
protein (histidine-tagged protein; expression plasmid/E. coli strain: pQE31-
prePHYH/M15 
41
). 
Other recombinant proteins may be produced as well. A useful one for the PEX5-centered 
in vitro assays is the glutathione S-transferase-ubiquitin fusion protein (GST-Ub), a 
dominant-negative version of ubiquitin 
21
 (see Table 1). This protein is expressed in large 
amounts in E. coli BL21(DE3) and purified using glutathione-sepharose™ 4B beads (GE 
Healthcare) 
64
. Other recombinant proteins which may be useful in some experiments are: 
C1PEX5S (equivalent to C1PEX5L but derived from PEX5S; used as a negative control 
for C1PEX5L; 26); matPHYH (the mature form of human phytanoyl-CoA hydroxylase; 
29 
used as a negative control for prePHYH; 
3
); and PEX19 (a peroxin with no role in the PIM, 
which is sometimes used as negative control for histidine-tagged recombinant proteins;  
65
. 
As the four recombinant proteins listed above, these proteins are also N-terminally 
histidine-tagged proteins. All are obtained in large amounts from E. coli transformed with 
the corresponding expression plasmids. With the exception of histidine-tagged PEX5L, 
which requires an extra chromatography step (e.g., anionic exchange on a Bio-Scale™ 
Mini Macro-Prep
®
 High Q column (BioRad) using a 300-800 mM NaCl gradient), all other 
histidine-tagged recombinant proteins are obtained with adequate purity (>90%) after a 
single immobilized metal-affinity chromatography step using a nickel-nitrilotriacetic acid 
matrix. Note that all these recombinant proteins are soluble and stable when handled as 
suggested here. However, if necessary, their monodispersity can be easily assessed by size-
exclusion chromatography or native-PAGE 
13,50
. Below, a general protein purification 
protocol, as well as a buffer exchange procedure for -70 ºC storage is provided. 
 
1. Inoculate a Petri dish containing LB/Agar plus the appropriate antibiotic(s) with E. coli 
cells harbouring the relevant expression plasmid. Incubate overnight at 37 ºC. 
2. Pick a colony and use it to inoculate 25 mL of LB + antibiotic(s). Grow this starter 
culture at 37 ºC with shaking overnight. 
3. The following day, dilute the starter culture with 500 mL of LB + antibiotic(s). Grow 
at 37 ºC with shaking for 1.5-2 h, or until OD600 nm= 0.6-0.8. 
4. Induce protein expression with 500 µL of 1 M IPTG (1 mM final concentration). Keep 
at 37 ºC with shaking for 3 h. 
5. Centrifuge the culture at 4,500g, 4 ºC, for 15 min to collect cells. Discard the 
supernatant. 
■ PAUSE POINT Cell pellets can be stored at -70 ºC for several months.  
6. Resuspend the cell pellet in 30 mL of Lysis buffer. Use Lysis buffer A for PEX5, 
C1PEX5L, C1PEX5S, NDPEX14 and PEX19 and Lysis buffer B for prePHYH and 
matPHYH. 
7. Disrupt cells by sonication for about 4 min in 10-15 sec pulses (10% output power, 
40% duty cycle). 
▲CRITICAL STEP Ensure that the sample is always cold. Keep it on ice and pause 
sonication as needed.  
8. Transfer the E. coli homogenate to a centrifuge tube (e.g., for rotor SS-34) and 
centrifuge suspension at 12,000g, 4 ºC for 20 min. Collect the clarified lysate and 
discard the pellet. 
9. (Optional additional step) This step is ONLY used for purification of recombinant 
C1PEX5L, C1PEX5S and PEX19. Put the clarified lysate in a boiling water bath for 
30 
5 min. Cool on ice for 5 min and centrifuge suspension at 12,000g, 4 ºC for 20 min. 
Discard the pellet. 
▲CRITICAL STEP This will denature and precipitate most E. coli proteins leaving 
the largely natively unfolded C1PEX5L, C1PEX5S and PEX19 recombinant 
proteins in solution. Thus, sample complexity is dramatically decreased, increasing the 
purity of the final protein preparation. 
10. Add the clarified lysate to 1.5 mL (bed volume) of HIS-Select® Nickel Affinity Gel 
beads that were previously washed two times with 3 volumes of ddH2O and 
equilibrated 3 times with 3 volumes of lysis buffer (minus DTT and PMSF). Incubate 
at 4 ºC for 2 h with gentle agitation. 
11. Spin down for 2 sec at 600g to collect beads. Discard the supernatant. 
12. Add 15 mL of Washing buffer A (for PEX5, C1PEX5L, C1PEX5S, NDPEX14 and 
PEX19) or Washing buffer B (for prePHYH and matPHYH) to the beads. Mix by 
inverting the tube a few times and centrifuge as above. Discard the supernatant. Repeat 
this step twice.  
13. Add 4.5 mL of Elution buffer and incubate at 4 ºC for 10 min with agitation. Spin 
down for 2 sec at 600g to collect beads and recover the supernatant (containing the 
eluted protein). Repeat the elution step and pool the 2 elutions. 
14. Using Vivaspin® 2 Sample concentrators concentrate the eluted protein to ~200 µL. 
Dilute to 2 mL (final volume) with Protein storage buffer and concentrate again to 
~200 µL. Repeat this step 3 more times. 
15. Collect the concentrated protein in an ice-cold microtube, and centrifuge for 20 min at 
11,300g, 4 ºC, to remove any agarose beads. Collect the supernatant and store 10-µL 
aliquots at -70 ºC after flash freezing in liquid nitrogen. 
■ PAUSE POINT Aliquots kept at -70 ºC and not subjected to multiple freeze/thaw 
cycles are stable up to one year. 
16. Estimate protein titer (e.g., Bradford protein assay) and analyze protein purity by SDS-
PAGE. 
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